' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID


Gewähltes Keyword: Bortezomib

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Fuchs, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Bartsch, R; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R;
BMC Cancer. 2018; 18(1): 1074
Originalarbeiten (Zeitschrift)
[Standardisation of the Initial Treatment of Severely Burned Patients: The Necessary Transfer of Concepts from Trauma Care].
Münzberg, M; Harbers, T; Kneser, U; Grützner, PA; Reichert, B; Kremer, T; Wölfl, CG; Horter, J; Hirche, C;
Zentralbl Chir. 2016; 141(6):654-659
Originalarbeiten (Zeitschrift)
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).
Willenbacher, W; Thangavadivel, S; Greil, R; Willenbacher, E; Weger, R; Manzl, C; Jöhrer, K; Brunner, A;
Leuk Lymphoma. 2016; 57(10):2330-2341
Originalarbeiten (Zeitschrift)
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Ludwig, H; Greil, R; Masszi, T; Spicka, I; Shpilberg, O; Hajek, R; Dmoszynska, A; Paiva, B; Vidriales, MB; Esteves, G; Stoppa, AM; Robinson, D; Chaturvedi, S; Ataman, O; Enny, C; Feng, H; van de Velde, H; Viterbo, L;
Br J Haematol. 2015; 171(3):3-54
Originalarbeiten (Zeitschrift)
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak, T; Huang, H; Jin, J; Zhu, J; Liu, T; Samoilova, O; Pylypenko, H; Verhoef, G; Siritanaratkul, N; Osmanov, E; Alexeeva, J; Pereira, J; Drach, J; Mayer, J; Hong, X; Okamoto, R; Pei, L; Rooney, B; van de Velde, H; Cavalli, F;
N Engl J Med. 2015; 372(10): 944-953.
Originalarbeiten (Zeitschrift)
Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons.
Staff, NP; Podratz, JL; Grassner, L; Bader, M; Paz, J; Knight, AM; Loprinzi, CL; Trushina, E; Windebank, AJ;
Neurotoxicology. 2013; 39: 124-131.
Originalarbeiten (Zeitschrift)
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig, H; Adam, Z; Hajek, R; Greil, R; Tóthová, E; Keil, F; Autzinger, EM; Thaler, J; Gisslinger, H; Lang, A; Egyed, M; Womastek, I; Zojer, N;
J Clin Oncol. 2010; 28(30): 4635-4641.
Originalarbeiten (Zeitschrift)
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Schmid, P; Kühnhardt, D; Kiewe, P; Lehenbauer-Dehm, S; Schippinger, W; Greil, R; Lange, W; Preiss, J; Niederle, N; Brossart, P; Freier, W; Kümmel, S; Van de Velde, H; Regierer, A; Possinger, K;
Ann Oncol. 2008; 19(5):871-876
Originalarbeiten (Zeitschrift)
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld, P; Hajek, R; Nagler, A; Spencer, A; Bladé, J; Robak, T; Zhuang, SH; Harousseau, JL; Orlowski, RZ;
Cancer. 2008; 112(7): 1529-1537.
Originalarbeiten (Zeitschrift)